Oxidative stress markers may not be early markers of doxorubicin-induced cardiotoxicity in rabbits

Experimental and Therapeutic Medicine

Volumn 2, Issue 5, 2011, Pages 947-950

  Lai, Renchun ^a   Long, Yuhui ^a   Li, Qiuli ^a   Zhang, Xu ^a   Rong, Tiehua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Cardiotoxicity; Doxorubicin; Oxidative stress markers

Indexed keywords

DOXORUBICIN; GLUTATHIONE PEROXIDASE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE INJURY; MALE; NONHUMAN; OXIDATIVE STRESS; RABBIT; SCORING SYSTEM;

EID: 79960231299     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.306     Document Type: Article

References (18)

1. Torrisi R, Cardillo A, Cancello G, et al: Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer. Clin Breast Cancer 10: 483-488, 2010.
2. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML and Lipshultz SE: Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 15: 1544-1552, 1997.
3. Alvarez JA, Scully RE, Miller TL, Armstrong FD, Constine LS, Friedman DL and Lipshultz SE: Long-term effects of treatments for childhood cancers. Curr Opin Pediatr 19: 23-31, 2007.
4. Li K, Sung RYZ, Huang WZ, et al: Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 113: 2211-2220, 2006.
5. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 5: 106-130, 2006.
6. Horacek JM, Vasatova M, Ticky M, Pudil R, Jebavy L and Maly J: The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia. Exp Oncol 32: 97-99, 2010.
7. Horacek JM, Ticky M, Jebavy L, Pudil R, Ulrychova M and Maly J: Use of multiple biomarkers for evaluation of anthracycline-induced cardiotoxicity in patients with acute myeloid leukemia. Exp Oncol 30: 157-159, 2008.
8. Faber M, Coudray C, Hida H, Mousseau M and Favier A: Lipid peroxidation products, and vitamin and trace element status in patients with cancer before and after chemotherapy, including adriamycin. A preliminary study. Biol Trace Elem Res 47: 117-123, 1995.
9. Kaya E, Keskin L, Aydogdu I, Kuku I, Bayraktar N and Erkut MA: Oxidant/antioxidant parameters and their relationship with chemotherapy in Hodgkin's lymphoma. J Int Med Res 33: 687-692, 2005.
10. Mercuro G, Cadeddu C, Piras A, et al: Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 12: 1124-1133, 2007.
11. Horino N, Kobayashi Y and Usui T: Elevation of lipid peroxide in children treated with a combination of chemotherapeutic agents including doxorubicin. Acta Paediatr Scand 72: 549-551, 1983.
12. Lai RC, Wang XD, Zhang X, Lin WQ and Rong TH: Heart fatty acid-binding protein may not be an early biomarker for anthracycline-induced cardiotoxicity in rabbits. Med Oncol: Feb. 10, 2011 (E-pub ahead of print).
13. Billingham ME, Mason JW, Bristow MR and Daniels JR: Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62: 865-872, 1978.
14. Wallace KB: Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 93: 105-115, 2003.
15. Berthiaume JM and Wallace KB: Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol 23: 15-25, 2007.
16. Milei J, Boveris A, Llesuy S, Molina HA, Storino R, Ortega D and Milei SE: Amelioration of adriamycin-induced cardiotoxicity in rabbits by prenylamine and vitamins A and E. Am Heart J 111: 95-102, 1986.
17. Sun X, Zhou Z and Kang YJ: Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart. Cancer Res 61: 3382-3387, 2001.
18. Van Vleet JF and Ferrans VJ: Clinical and pathologic features of chronic adriamycin toxicosis in rabbits. Am J Vet Res 41: 1462-1469, 1980.